louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02380989: Integrative Ayurveda Healing Relieves Minor Sports Injury Pain
Official title: Integrative Ayurveda Healing Relieves Minor Sports Injury Pain:Results of a Multicenter Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acute Pain
Sports Injury
Keywords: Ayurveda
Acute pain
Sports Injury
Lead sponsor: Adwin Life Care
Sponsor class: INDUSTRY
Collaborators: name: NMP Medical Research Institute
First posted: 2015-03-05
Enrollment: 210
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Sports-related soft tissue injuries, such as sprains, strains, and contusions, are a common painful condition. Current treatment includes oral nonsteroidal anti-inflammatory drugs (NSAIDs), which have a high incidence of intolerable gastrointestinal side effects.

Ancient Indian healing system, Ayurveda addresses the need of sports medicine up to certain extent. In practice, there are different treatment modalities for injuries, uses of drugs \& dietetics as well as practices of rehabilitation. Although, previous evidences support the efficacy of ayurveda practices with significant reduction in pain, joint tenderness, joint swelling, mobility restriction and early morning joint stiffness. But there is no treatment studies have been performed to evaluate the clinical outcome for specific sports injuries.

This study assessed the efficacy and safety of ayurveda gel and patches applied to the painful injury site for the treatment of acute minor sports injury pain.


Eligibility criteria: Inclusion Criteria:

* inversion ankle injury;
* injury sustained during sporting activity

Exclusion Criteria:

* other lower limb injury;
* concurrent fracture with or without dislocation or with or without complete rupture;
* surgery for ankle injury.

Primary outcomes:
measure: Change in Pain intensity (VAS)
timeFrame: baseline to 3, 7 and 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Mahesana
country: India
facility: NMP Medical Research Institute
state: Gujarat
city: Satnali
country: India
facility: Khatri educational trust
state: Hariyana
city: Jaipur
country: India
facility: GyanSanjeevani
state: Rajasthan
Study officials:
affiliation: NMP Medical Research Institute
name: Archanaben Nachiket, MA
role: PRINCIPAL_INVESTIGATOR
affiliation: NMP Medical Research Institute
name: Neha Sharma, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00710489: Potential Research Study Participant Registry
Official title: Potential Research Study Participant Registry
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acne
Actinic Keratosis
Dysplastic Nevi
Eczema
Psoriasis
Skin Cancer
Rosacea
Leg Ulcers
Foot Ulcers
Atopic Dermatitis
Keywords: Acne
Actinic Keratosis
Dysplastic Nevi
Eczema
Psoriasis
Vitiligo
Skin Cancer
Rosacea
Leg or Foot Ulcers
Atopic Dermatosis
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2008-07-04
Enrollment: 265
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult community members with an interest in one or more of the following dermatologic conditions: Acne, Actinic Keratosis, Blistering Diseases, Dysplastic Nevi (mole), Eczema, Psoriasis, Vitaligo, Skin Cancer Prevention, Skin Cancer Treatment, Phototherapy Treatment Options, Rosacea, Leg or Foot Ulcers, Lichen Planus, Atopic Dermatosis, Canker Sores,others as indicated.

Brief summary: The purpose of the potential research study participant registry is to keep potential research subjects informed about any future research studies in which they may meet the criteria for enrollment. The purpose of this study is also to assist current and future clinical trials with recruitment of subjects.

Detailed description: Methods:

Subjects will self identify themselves via the UCDMC Dermatology website to complete a survey regarding their interest in learning about future dermatology clinical research projects. Subjects provide contact information and check of a list of potential topics of interest.

Procedures:

Potential participants will find a link on the UCDMC Dermatology website to our registry. The potential participant will read information about the registry. If they wish additional information, they can follow a link to the potential research registry consent form. At this stage, the potential participant may answer, "no" to the consent form and they will be redirected back to the Clinical trials website. If they answer, "yes" then they will be linked to the registry questionnaire. The potential subject would then decide if they want to participate in the registry and if so what information they want to provide. The Clinical Research Coordinators would contact potential study participants to see if they meet the eligibility criteria for any of our current studies.

Eligibility criteria: Inclusion Criteria:

* Over 18 years of age

Exclusion Criteria:

* Under 18 years of age

Primary outcomes:
measure: Identify Dermatology Clinical research topics of interest in the community.
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California, Davis
state: California
Study officials:
affiliation: University of California, Davis
name: Fu-Tong Liu, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00255489: A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer
Official title: A Phase I Study of ZD1839 (Iressa) and Palliative Thoracic Radiotherapy in Patients With Non-small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Non-small-cell Lung Cancer
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2005-11-21
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to characterize the safety profile of ZD1839 in combination with Palliative thoracic Radiotherapy in patients with non-small cell lung cancer


Eligibility criteria: Inclusion Criteria:

* Provision of written informed consent
* Patients requiring low dose palliative thoracic irradiation to a field size of less than or equal to 150cm2
* Histologically or cytologically conformed non-small cell lung cancer
* Aged 18 or over

Exclusion Criteria:

* Previous thoracic radiotherapy
* Any condition that may pre-dispose the patient to suffer an individual drug-relaged DLT (dose limiting toxicity) event
* Known hypersensitivity to any component of study medication

Primary outcomes:
measure: To characterize the safety profile of ZD 1839 in these patients
Secondary outcomes:
measure: To measure the quality of life compared to baseline
measure: To measure the change in disease related symptoms compared to baseline
Other outcomes:
Locations:
city: Edinburgh
country: United Kingdom
facility: Research Site
city: Leeds
country: United Kingdom
facility: Research Site
Study officials:
affiliation: AstraZeneca
name: AstraZeneca Iressa Medical Sciences Director, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01266889: Measurement of Cerebral Oxygenation Using NIRS Method in the Preterm Infants With Intracranial Haemorrhagia
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cerebral Oxygenation, Intracranial Haemorrhagia
Keywords: preterm infant,cerebral oxygenation, intracranial haemorrhagia
Lead sponsor: Zekai Tahir Burak Women's Health Research and Education Hospital
Sponsor class: OTHER
First posted: 2010-12-24
Enrollment: 20
Sex: ALL
Minimum age (years): 1
Maximum age (years): 3
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: primer care clinic

Brief summary: The aim of the study was investigated the cerebral tissue oxygenation index (c-TOI) measured by near infrared spectroscopy (NIRS)in the preterm infants with intracranial haemorrhagia.


Eligibility criteria: Inclusion Criteria:

.\<34 gestation week preterm infants with intracranial haemorrhagia

Exclusion Criteria:

* sepsis
* NEC
* congenital abnormalities
* hydrocephalus
* intracranial infections

Primary outcomes:
measure: cerebral oxygenation
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Melek Akar
state: Hamamönü
Study officials:
References:
Clinical trial NCT00419289: Optimizing the Effect of COPD Rehabilitation
Official title: Rehabilitation of COPD Patients: Can the Effect be Prolonged by Follow-up and Continued Rehabilitation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: COPD, rehabilitation, quality of life
Lead sponsor: Glostrup University Hospital, Copenhagen
Sponsor class: OTHER
Collaborators: name: Ministry of the Interior and Health, Denmark
First posted: 2007-01-08
Enrollment: 120
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Patients with Chronic Obstructive Pulmonary Disease (COPD) may benefit from an 8-week pulmonary rehabilitation programme. However, the effect of the programme tends to attenuate with time. Patients who complete the programme are randomized to continued rehabilitation follow-up and control follow-up.

Detailed description: Patients with Chronic Obstructive Pulmonary Disease (COPD) may benefit from an 8-week pulmonary rehabilitation programme according to guidelines of the Danish Society of Pulmonary Medicine. However, the effect of programme tends to attenuate with time. Patients who complete the programme are randomized to continued rehabilitation follow-up and control follow-up.

Eligibility criteria: Inclusion Criteria:

* FEV1 \< 60% of expected

Exclusion Criteria:

* Other severe chronic conditions

Primary outcomes:
measure: Disease specific Quality of Life
measure: Work Capacity
Secondary outcomes:
measure: Number of days admitted to hospital
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Department of Internal Medicine M, Glostrup University Hospital
Study officials:
affiliation: Glostrup University Hospital, Copenhagen
name: Susanne Vest, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05369689: Stereotactic Radiosurgery Prognosis Assessment for Spinal Tumors Based on Radiomics
Official title: Stereotactic Radiosurgery Prognosis Assessment for Spinal Tumors Based on Radiomics
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Stereotactic Radiosurgery
Spinal Tumor
Radiomics
Prognosis
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2022-05-11
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who had spinal tumors and completed CT, MRI, PET-CT examination before and after stereotactic radiosurgery.

Brief summary: This study aims to assess multimodal Radiomics-based prediction model for prognostic prediction in spinal tumors.

Detailed description: Sensitivity for prediction recurrence and survival of currently available prognostic scores is limited. This study proposes to establish a multimodal radiomics model for identifying tumor recurrence and prognostic prediction of spinal tumors. The study will investigate the relationship between the radiomics and the tumor microenvironment. The study includes the construction of multimodal radiomics-based prediction model and the validation of the prediction model.

Eligibility criteria: Inclusion Criteria:

A diagnosis of spinal tumors for which SBRT is appropriate Karnofsky Performance Status \>60 Life expectancy of at least 3 months No contraindication to undergoing MR imaging Age \>18 Complete the CT MRI or PET-CT examination before and after treatment Accept stereotactic radiosurgery

Exclusion Criteria:

Subjects unable to undergo MRI (includes non-MRI compatible material or devices and severe claustrophobia) Subjects with prior procedural intervention to the involved vertebral body that would result in artifact (kyphoplasty, screw and/or rod placement); minimally invasive surgery without instrumentation of the involved vertebral body and instrumentation immediately above or below the index lesion is allowed.

Subjects with spinal cord compression; minimally invasive "separation" surgery to first resect the epidural component is allowed Pregnant or breast-feeding women Allergy to standard IV contrast agents used in MRI

Primary outcomes:
measure: PFS
timeFrame: 1 years
Secondary outcomes:
measure: Overall survival (OS)
timeFrame: 1 years
measure: ORR
timeFrame: 3 months
measure: DCR
timeFrame: 3 months
measure: Recurrence free survival (RFS)
timeFrame: 1 year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Department of Radiation Oncology Cancer Center, Peking University Third Hospital 49# North Garden Rd.,Haidian Dist.
state: Beijing
Study officials:
References:
Clinical trial NCT06715189: Correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic Fibrosis in MASlD With type2 Diabetes Mellitus
Official title: Correlation Between Serum Adiponectin and Resistin Levels and Degree of Hepatic Fibrosis In Metabolic Dysfunction _Associated Steatotic Liver Disease (MASLD)With Type2 Diabetes Mellitus
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Hepatic Fibrosis
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2024-12-04
Enrollment: 80
Sex: ALL
Minimum age (years): 30
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: MASLD patients with hepatic fibrosis groupA,MASLD patients without hepatic fibrosis

Brief summary: Metabolic dysfunction asociated steatotic liver disease prevalence is 25%world wide diabetic patients have a risk for MASLD then have hepatic fibrosis so we study correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic fibrosis In Metabolic dysfunction asociated steatotic liver disease in patients with type2 Diabetes Mellitus


Eligibility criteria: Inclusion Criteria:

* patients of both sex who have type2 Diabetes Mellitus for less than five years

Exclusion Criteria:alcholics ,chronic liver disease elevated liver functions , sever infection

-

Primary outcomes:
measure: degree of hepatic fibrosis in MASLD with type 2 diabetes mellitus
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023 Sep 30;32(3):197-213. doi: 10.7570/jomes23052. Epub 2023 Sep 13.
citation: Marchesini G, Vettor R, Pinzani M. MASLD emerging from the fog of fatty liver. J Hepatol. 2024 Feb;80(2):178-180. doi: 10.1016/j.jhep.2023.10.011. Epub 2023 Nov 30. No abstract available.
citation: Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, Yang JD, Tan E, Muthiah MD. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023 Feb;29(Suppl):S32-S42. doi: 10.3350/cmh.2022.0365. Epub 2022 Dec 14.
citation: Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018 Jan;67(1):123-133. doi: 10.1002/hep.29466. Epub 2017 Dec 1.
Clinical trial NCT04223089: Accuracy of TCOM vs NIRS in Predicting Wound Outcomes in Patients Treated With or Without Revascularization
Official title: Accuracy of Transcutaneous Oxygen Monitoring (TCOM) vs Near Infrared Spectroscopy (NIRS) in Predicting Wound Outcomes in Patients Treated With or Without Revascularization
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Wound Heal
Lead sponsor: University of Kansas Medical Center
Sponsor class: OTHER
First posted: 2020-01-10
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This prospective study will include up to 200 adult patients who present with non-healing lower extremity wounds to the University of Kansas Medical Center. Patients will be grouped into two study arms depending on the degree of tissue ischemia (above or below 40 mmHg) and required treatment (conservative wound care alone or revascularization). Relevant clinical information will be obtained from patients' medical records including demographics, clinical history, intervention details, surgical records, and imaging data. Wound healing will be assessed at presentation, at the time of revascularization (pre and post-operative), and every 6 weeks thereafter by clinical assessment, Wagner classification, TCOM PO2 measurements and NIRS PO2 measurements. TCOM will guide treatment decisions and management, which is the current standard of care.

Brief summary: The primary purpose of this project is to compare the accuracy of transcutaneous oxygen monitoring and near infrared spectroscopy in assessing cutaneous oxygen levels in chronic wounds of patients following revascularization procedures as well as those with conservatively managed chronic wounds. This study will also compare the efficiency and practicality of both methods in guiding treatment decisions and management of these wounds.


Eligibility criteria: Inclusion Criteria:

* Are between the ages of 18-85
* Presented with a non-healing lower extremity wound and have a Wagner classification for wound healing of grade 1 or 2

Exclusion Criteria:

* Wagner grade 3-5
* Congestive heart failure (CHF) with a left ventrical ejection fraction (LVEF) \< 30%
* Have had a below the knee drug eluting stent placed (paclitaxel is chemo, can make wounds worse)

Primary outcomes:
measure: Accuracy of NIRS measurements
timeFrame: From presentation to wound healing or amputation (approximately 6 months at most)
Secondary outcomes:
Other outcomes:
Locations:
city: Kansas City
country: United States
facility: University of Kansas Medical Center
state: Missouri
Study officials:
affiliation: KUMC
name: Adam Alli, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04347889: Preventing COVID-19 in Healthcare Workers With HCQ: A RCT
Official title: Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19: A RCT
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Covid-19
Keywords: covid-19
healthcare workers
prophylaxis
hydroxychloroquine
Lead sponsor: Stony Brook University
Sponsor class: OTHER
First posted: 2020-04-15
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Open label, controlled, RCT
Primary purpose: PREVENTION

Brief summary: Healthcare workers (HCW) at risk of Covid-19 will have baseline serology for SARS-CoV-2 to see if they are already immune to Covid-19. HCW will get baseline assessment and if meeting inclusion criteria and no exclusion criteria they will be randomized in a 2:1 ratio to hydroxychloroquine or Vitamin C on a weekly basis for three months. Subjects will complete daily diary of symptoms and temperature, and will have repeat SARS-CoV-2 serology at 6 weeks and 3 months to determine seroconversion.

Detailed description: Healthcare workers (HCW) at risk of Covid-19 will have baseline serology for SARS-CoV-2 to see if they are already immune to Covid-19. HCW will get baseline assessment and if meeting inclusion criteria and no exclusion criteria they will be randomized in a 2:1 ratio to hydroxychloroquine or Vitamin C on a weekly basis for three months. Subjects will complete daily diary of symptoms and temperature, and will have repeat SARS-CoV-2 serology at 6 weeks and 3 months to determine seroconversion.

Eligibility criteria: Inclusion Criteria:

* Healthcare worker at risk of Covid-19

Exclusion Criteria:

* Known hypersensitivity or allergic reactions to 4-aminoquinoline compounds or its ingredients.
* Current, or history of, ocular macular disease or retinal damage.
* Current, or history of, subnormal glomerular filtration.
* Current use of tamoxifen citrate.
* Current, or history of, cardiomyopathy, atrial, nodal, or ventricular arrhythmias, torsades de pointes, conduction disorders (bundle branch block/atrio-ventricular heart block) or biventricular hypertrophy.
* Subjects taking other drugs that have the potential to prolong QT interval if taken with HCQ.

Primary outcomes:
measure: COVID-19 Seroconversion rate
timeFrame: 3 months
Secondary outcomes:
measure: Admission for Covid-19
timeFrame: 3 months
Other outcomes:
Locations:
Study officials:
References: